MCKNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
MCKESSON CORP
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1010.43+5.59 (+0.56%)
Close on Oct 19, 2026
- Market cap
- $120.44B
- P/E (TTM)
- 27.1
- Dividend yield
- 0.31%
Share price
+$224.43 (+28.55%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
MCKESSON CORP grew revenue 8.8% to $410.98B over the twelve months to Jun 30, 2026. Operating income rose 46.6% to $6.50B, moving the operating margin from 1.2% to 1.6%. Free cash flow was $6.42B, up 6.8% from a year earlier.
Revenue
$410.98B
+8.8% vs. a year earlier
Operating income
$6.50B
+46.6% vs. a year earlier
Free cash flow
$6.42B
+6.8% vs. a year earlier
EPS, diluted
$37.35
+49.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $120.44B
- P/E ratio
- 27.1
- Price to sales
- 0.29
- Price to book
- –
- Dividend yield
- 0.31%
- Free cash flow yield
- 5.33%
Fundamentals
- Revenue
- $410.98B
- Net income
- $4.59B
- EPS, diluted
- $37.35
- Free cash flow
- $6.42B
- Book value per share
- -$35.57
- Diluted shares
- 119M
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$410.98B+8.8% YoY
Gross profit
$14.96B+11.2% YoY
Operating income
$6.50B+46.6% YoY
Net income
$4.59B+45.1% YoY
EPS, diluted
$37.35+49.0% YoY
Free cash flow
$6.42B+6.8% YoY
Reported periodTrailing twelve months